Cyclosporine- and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling.
- 1 September 1993
- journal article
- abstracts
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 73 (3) , 596-602
- https://doi.org/10.1161/01.res.73.3.596
Abstract
Cyclosporine A (CsA)-induced hypertension appears to be caused in part by neurogenic vasoconstriction, but the mechanism by which CsA activates the sympathetic nervous system is unknown. In T lymphocytes, the cellular target of CsA and the macrolide immunosuppressant FK506 (as complexes with their endogenous cytoplasmic receptors, or immunophilins) is the Ca(2+)-calmodulin-dependent phosphatase calcineurin. The presence of calcineurin and its colocalization with immunophilin in the brain led us to hypothesize that the phosphatase also mediates CsA-induced sympathetic activation. We now report that sympathetic activity and arterial pressure in rats are increased not only by CsA but also by FK506, which is structurally unrelated to CsA but inhibits the same calcineurin-sensitive T-cell signaling pathway. In contrast, sympathetic activity and blood pressure are not increased by rapamycin, which forms an immunophilin complex that does not bind calcineurin. Furthermore, CsA- and FK506-induced sympathetic activation is attenuated for drug analogues possessing modest changes in molecular structure in a way that closely parallels the ability of each analogue to inhibit calcineurin-mediated T-cell signaling. These results implicate an important role for extralymphoid (ie, neuronal) calcineurin in mediating immunosuppressive drug toxicity.Keywords
This publication has 38 references indexed in Scilit:
- FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurinNature, 1992
- Cyclosporine causes sympathetically mediated elevations in arterial pressure in rats.Hypertension, 1991
- Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexesCell, 1991
- Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin.Proceedings of the National Academy of Sciences, 1990
- A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilinNature, 1989
- A Placebo-Controlled, Double-Blind, Randomized Trial of Cyclosporine Therapy in Active Chronic Crohn's DiseaseNew England Journal of Medicine, 1989
- FK-506 — How much potential?Immunology Today, 1989
- Preliminary Results of a Double-Blind, Randomized, Placebo-Controlled Trial of Cyclosporine in Myasthenia GravisNew England Journal of Medicine, 1987
- Systemic hypertension after cardiac transplantation: Effect of cyclosporine on the renin-angiotensin-aldosterone systemThe American Journal of Cardiology, 1985
- Detection of intracellular Ca2+ transients in sympathetic neurones using arsenazo IIINature, 1983